中国医院用药评价与分析Issue(6)：765-768,769,5.DOI:10.14009/j.issn.1672-2124.2015.06.023
福莫特罗与茚达特罗治疗慢性阻塞性肺疾病的系统评价Δ
Systematic Evaluation of Formoterol and Indatero in the Treatment of Chronic Obstructive Pulmonary DiseaseΔ
摘要
Abstract
OBJECTIVE:To evaluate the efficacy and safety of fomoterol and indatero in the treatment of chronic obstructive pulmonary disease ( COPD) .METHODS: The databases either in English or Chinese were searched for randomized controlled trials ( RCTs) or systematic review of formoterol as compared with placebo or indacaterol for treatment of COPD.The included RCTs were subjected to evaluation of the methodological quality and meta-analysis. RESULTS:Compared with placebo, formoterol significantly improved the quality of life of patients with COPD, and the difference was statistically significant (P<0.01);compared with formoterol, indinavir significantly improved FEV1 in patients with COPD, and the difference was statistically significant ( P<0.01 ) .There were no significant differences between formoterol and placebo or indinavir in other indices ( P >0.05 ) .CONCLUSIONS: Both formoterol and indacaterol can improve the quality of life of patients with COPD, and indacaterol also can significantly improve lung function in patients with COPD, indatero, therefore, is worthy of wide clinical application in the treatment of COPD.关键词
肺疾病,慢性阻塞性/Meta分析/随机对照试验/福莫特罗/系统评价Key words
Pulmonary disease, Chronic obstructive/Meta-analysis/Randomized controlled trial/Formoterol/Systematic evaluation分类
医药卫生引用本文复制引用
刘秀书,曹艳,杜岚,邹爱英,尹世强..福莫特罗与茚达特罗治疗慢性阻塞性肺疾病的系统评价Δ[J].中国医院用药评价与分析,2015,(6):765-768,769,5.基金项目
“十二五”国家科技支撑计划课题“安全合理用药评价和干预技术研究与应用”（No．2013BAI06B04）。 （）
